Your browser doesn't support javascript.
loading
Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia.
Brown, Jennifer R; Harb, Wael A; Hill, Brian T; Gabrilove, Janice; Sharman, Jeff P; Schreeder, Marshall T; Barr, Paul M; Foran, James M; Miller, Thomas P; Burger, Jan A; Kelly, Kevin R; Mahadevan, Daruka; Ma, Shuo; Li, Yan; Pierce, Daniel W; Barnett, Evelyn; Marine, Jeffrey; Miranda, Monika; Azaryan, Ada; Yu, Xujie; Nava-Parada, Pilar; Mei, Jay; Kipps, Thomas J.
Afiliación
  • Brown JR; Dana-Farber Cancer Institute, Boston, MA, USA jennifer_brown@dfci.harvard.edu.
  • Harb WA; Horizon Oncology Center, Lafayette, IN, USA.
  • Hill BT; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, OH, USA.
  • Gabrilove J; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Sharman JP; Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR, USA.
  • Schreeder MT; Clearview Cancer Institute, Huntsville, AL, USA.
  • Barr PM; Hematology/Oncology, University of Rochester Medical Center, Rochester, NY, USA.
  • Foran JM; Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA.
  • Miller TP; University of Arizona Cancer Center, Tucson, AZ, USA.
  • Burger JA; Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX, USA.
  • Kelly KR; University of Texas Health Science Center at San Antonio, CTRC Institute for Drug Development, TX, USA.
  • Mahadevan D; The West Clinic, University of Tennessee Health Sciences Center, ACORN Research, LLC, Memphis, TN, USA.
  • Ma S; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
  • Li Y; Department of Translational Medicine, Celgene Corporation, San Francisco, CA, USA.
  • Pierce DW; Department of Translational Medicine, Celgene Corporation, San Francisco, CA, USA.
  • Barnett E; Celgene Corporation, Summit, NJ, USA.
  • Marine J; Celgene Corporation, Summit, NJ, USA.
  • Miranda M; Celgene Corporation, Summit, NJ, USA.
  • Azaryan A; Celgene Corporation, Berkeley Heights, NJ, USA.
  • Yu X; Celgene Corporation, Berkeley Heights, NJ, USA.
  • Nava-Parada P; Celgene Corporation, Summit, NJ, USA.
  • Mei J; Celgene Corporation, Summit, NJ, USA.
  • Kipps TJ; University of California, San Diego, Moores Cancer Center, La Jolla, CA, USA.
Haematologica ; 101(7): e295-8, 2016 07.
Article en En | MEDLINE | ID: mdl-27151992
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Pirimidinas / Acrilamidas / Proteínas Tirosina Quinasas / Leucemia Linfocítica Crónica de Células B Tipo de estudio: Clinical_trials Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Haematologica Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Pirimidinas / Acrilamidas / Proteínas Tirosina Quinasas / Leucemia Linfocítica Crónica de Células B Tipo de estudio: Clinical_trials Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Haematologica Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos